Approved for sale in Europe, CE Registration #518356 .
"US Investigational Device, not currently available for sale in the US .
Initial study of the device in ALS provided the feasibility of using diaphragmic pacing to slow the decline in a patient's Forced Vital Capacity and delay the onset of respiratory failure. Data from our pilot study revealed the average pre-implant rate of decline was calculated at -2.8% per month and for patients with at least 9 months post-implant follow-up the rate improved to
-1.0% per month.
We are also investigating to determine if the NeuRx DPS™ may be effective in ventilatory support of patients with ALS either decreasing or eliminating the need for negative or positive pressure mechanical ventilation.
Or for information about the open ALS clinical trial please contact:
|University Hospitals of Cleveland
Cleveland, OH 44106
|Mary Jo Elmo, ACNP
Office (216) 844-8594
|#2||Johns Hopkins University
Baltimore, MD 21287
|Laura Clawson-Research Coordinator
Office (410) 955-8511
Stanford, CA 94305
|Shirley Paulose-Research Assistant, Neurology
Office (650) 724-3792
|#4||Methodist Neurological Institute
Houston, Texas 77030
|Luis F. Lay, Jr.-Senior Research Coordinator
Office (713) 441-3057
|#5||Henry Ford Health System
Detroit, MI. 48202
|Helen Foley-Research Coordinator
Office (313) 916-3955
Jacksonville, FL 32224
|Karen Overstreet-ALS Research Coordinator
Office (904) 953-8946
|#7||California Pacific Medical Center (CPMC)
San Francisco, CA 94115
|Dallas Forshew-Manager, ALS Research